Select all docs (Max 200)
Narrow Results:
Publication Year
Personal Author
Resource Type General
Keywords
- Acute Coronary Syndrome 1
- Adenosine 1
- Antithrombin III 1
- biomarker 1
- Biomarkers 1
- bleeding complications 1
- cardiovascular risk 1
- Clopidogrel 1
- deep vein thrombosis 1
- Female 1
- Fibrin Fibrinogen Degradation Products 1
- Genomics 1
- genomics 1
- Hemorrhage 1
- Humans 2
- Male 1
- Middle Aged 1
- P-Selectin 1
- Peptide Hydrolases 1
- Peripheral Arterial Disease 1
- Platelet Aggregation Inhibitors 1
- Platelet inhibitor 1
- precision medicine 1
- Purinergic P2Y Receptor Antagonists 1
- Recurrence 1
- Risk Factors 1
- risk factors 1
- Ticagrelor 1
- transcriptomics 1
- Treatment Outcome 1
- Up-Regulation 1
- Venous Thrombosis 1
Select all docs (Max 200)
1 -
2 of 2 Results
SELECT A RANGE
SELECT A FORMAT
Refine Results
Refine Results:
- Acute Coronary Syndrome (1)
- Adenosine (1)
- Antithrombin III (1)
- biomarker (1)
- Biomarkers (1)
- bleeding complications (1)
- cardiovascular risk (1)
- Clopidogrel (1)
- deep vein thrombosis (1)
- Female (1)
- Fibrin Fibrinogen Degradation Products (1)
- Genomics (1)
- genomics (1)
- Hemorrhage (1)
- Humans (2)
- Male (1)
- Middle Aged (1)
- P-Selectin (1)
- Peptide Hydrolases (1)
- Peripheral Arterial Disease (1)
- Platelet Aggregation Inhibitors (1)
- Platelet inhibitor (1)
- precision medicine (1)
- Purinergic P2Y Receptor Antagonists (1)
- Recurrence (1)
- Risk Factors (1)
- risk factors (1)
- Ticagrelor (1)
- transcriptomics (1)
- Treatment Outcome (1)
- Up-Regulation (1)
- Venous Thrombosis (1)
- Whole Blood Gene Expression Analyses in Patients With Single Versus Recurrent Venous Thromboembolism:Lewis, Deborah A ;Stashenko, Gregg J12 2011 | Thromb Res. 2011; 128(6):536-540:IntroductionVenous thromboembolism may recur in up to 30% of patients with a spontaneous venous thromboembolism after a standard course of anticoagula...
- :Myers, Rachel A ;Ortel, Thomas L2 2024 | Arterioscler Thromb Vasc Biol. 44(2):423-434:Background:Identifying patients with the optimal risk:benefit for ticagrelor is challenging. The aim was to identify ticagrelor-responsive platelet tr...
Exit Notification/Disclaimer Policy
Links with this icon indicate that you are leaving the CDC website.
- The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
- Linking to a non-federal Website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
- You will be subject to the destination website's privacy policy when you follow the link.
- CDC is not responsible for Section 508 compliance (accessibility) on other federal or private websites.